Concomitant imatinib and ibrutinib in a patient with chronic myelogenous leukemia and chronic lymphocytic leukemia

por Shea, Lauren K., Mikhail, Fady M., Forero‐Torres, Andres, Davis, Randall S.
Publicado 2017

Real-world outcomes among patients with HER2+ metastatic breast cancer with brain metastases

por DeBusk, Kendra, Ike, Chiemeka, Lindegger, Nicolas, Schwartz, Naomi, Surinach, Andy, Liu, Yutong, Forero-Torres, Andres
Publicado 2022

A Phase Ib study of ruxolitinib + gemcitabine ± nab-paclitaxel in patients with advanced solid tumors

por Bauer, Todd M, Patel, Manish R, Forero-Torres, Andres, George, Thomas J, Assad, Albert, Du, Yining, Hurwitz, Herbert
Publicado 2018

Lower frequency of TLR9 variant associated with protection from breast cancer among African Americans

por Chandler, Madison R., Keene, Kimberly S., Tuomela, Johanna M., Forero-Torres, Andres, Desmond, Renee, Vuopala, Katri S., Harris, Kevin W., Merner, Nancy D., Selander, Katri S.
Publicado 2017

O-GlcNAcylation of GLI Transcription Factors in Hyperglycemic Conditions Augments Hedgehog activity: Hyperglycemic conditions upregulate GLI activity

por Das, Shamik, Bailey, Sarah K., Metge, Brandon J., Hanna, Ann, Hinshaw, Dominique C., Mota, Mateus, Forero-Torres, Andres, Chatham, John C., Samant, Rajeev S., Shevde, Lalita A.
Publicado 2018

A phase I/II study of preoperative letrozole, everolimus, and carotuximab in stage 2 and 3 hormone receptor-positive and Her2-negative breast cancer

por Vaklavas, Christos, Stringer-Reasor, Erica M., Elkhanany, Ahmed M., Ryan, Kevin J., Li, Yufeng, Theuer, Charles P., Acosta, Edward P., Wei, Shi, Yang, Eddy S., Grizzle, William E., Forero-Torres, Andres
Publicado 2023

An open‐label phase 2 trial of entospletinib in indolent non‐Hodgkin lymphoma and mantle cell lymphoma

por Andorsky, David J., Kolibaba, Kathryn S., Assouline, Sarit, Forero‐Torres, Andres, Jones, Vicky, Klein, Leonard M., Patel‐Donnelly, Dipti, Smith, Mitchell, Ye, Wei, Shi, Wen, Yasenchak, Christopher A., Sharman, Jeff P.
Publicado 2018

Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies

por Bartlett, Nancy L, Chen, Robert, Fanale, Michelle A, Brice, Pauline, Gopal, Ajay, Smith, Scott E, Advani, Ranjana, Matous, Jeffrey V, Ramchandren, Radhakrishnan, Rosenblatt, Joseph D, Huebner, Dirk, Levine, Pamela, Grove, Laurie, Forero-Torres, Andres
Publicado 2014

A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors

por de Vos, Sven, Forero-Torres, Andres, Ansell, Stephen M, Kahl, Brad, Cheson, Bruce D, Bartlett, Nancy L, Furman, Richard R, Winter, Jane N, Kaplan, Henry, Timmerman, John, Whiting, Nancy C, Drachman, Jonathan G, Advani, Ranjana
Publicado 2014

An open-label, pilot study of veliparib and lapatinib in patients with metastatic, triple-negative breast cancer

por Stringer-Reasor, Erica M., May, Jori E., Olariu, Eva, Caterinicchia, Valerie, Li, Yufeng, Chen, Dongquan, Della Manna, Deborah L., Rocque, Gabrielle B., Vaklavas, Christos, Falkson, Carla I., Nabell, Lisle M., Acosta, Edward P., Forero-Torres, Andres, Yang, Eddy S.
Publicado 2021

Phase 2, multicenter, open-label study of tigatuzumab (CS-1008), a humanized monoclonal antibody targeting death receptor 5, in combination with gemcitabine in chemotherapy-naive p...

por Forero-Torres, Andres, Infante, Jeffrey R, Waterhouse, David, Wong, Lucas, Vickers, Selwyn, Arrowsmith, Edward, He, Aiwu Ruth, Hart, Lowell, Trent, David, Wade, James, Jin, Xiaoping, Wang, Qiang, Austin, TaShara, Rosen, Michael, Beckman, Robert, von Roemeling, Reinhard, Greenberg, Jonathan, Saleh, Mansoor
Publicado 2013

Glembatumumab vedotin for patients with metastatic, gpNMB overexpressing, triple-negative breast cancer (“METRIC”): a randomized multicenter study

por Vahdat, Linda T., Schmid, Peter, Forero-Torres, Andres, Blackwell, Kimberly, Telli, Melinda L., Melisko, Michelle, Möbus, Volker, Cortes, Javier, Montero, Alberto J., Ma, Cynthia, Nanda, Rita, Wright, Gail S., He, Yi, Hawthorne, Thomas, Bagley, Rebecca G., Halim, Abdel-Baset, Turner, Christopher D., Yardley, Denise A.
Publicado 2021

Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study

por Dirix, Luc Y., Takacs, Istvan, Jerusalem, Guy, Nikolinakos, Petros, Arkenau, Hendrik-Tobias, Forero-Torres, Andres, Boccia, Ralph, Lippman, Marc E., Somer, Robert, Smakal, Martin, Emens, Leisha A., Hrinczenko, Borys, Edenfield, William, Gurtler, Jayne, von Heydebreck, Anja, Grote, Hans Juergen, Chin, Kevin, Hamilton, Erika P.
Publicado 2017

PIK3CA and MAP3K1 alterations imply luminal A status and are associated with clinical benefit from pan-PI3K inhibitor buparlisib and letrozole in ER+ metastatic breast cancer

por Nixon, Mellissa J., Formisano, Luigi, Mayer, Ingrid A., Estrada, M. Valeria, González-Ericsson, Paula I., Isakoff, Steven J., Forero-Torres, Andrés, Won, Helen, Sanders, Melinda E., Solit, David B., Berger, Michael F., Cantley, Lewis C., Winer, Eric P., Arteaga, Carlos L., Balko, Justin M.
Publicado 2019

Older patients (aged ≥60 years) with previously untreated advanced-stage classical Hodgkin lymphoma: a detailed analysis from the phase III ECHELON-1 study

por Evens, Andrew M., Connors, Joseph M., Younes, Anas, Ansell, Stephen M., Kim, Won Seog, Radford, John, Feldman, Tatyana, Tuscano, Joseph, Savage, Kerry J., Oki, Yasuhiro, Grigg, Andrew, Pocock, Christopher, Dlugosz-Danecka, Monika, Fenton, Keenan, Forero-Torres, Andres, Liu, Rachael, Jolin, Hina, Gautam, Ashish, Gallamini, Andrea
Publicado 2021

TBCRC 002: a phase II, randomized, open-label trial of preoperative letrozole with or without bevacizumab in postmenopausal women with newly diagnosed stage 2/3 hormone receptor-po...

por Vaklavas, Christos, Roberts, Brian S., Varley, Katherine E., Lin, Nancy U., Liu, Minetta C., Rugo, Hope S., Puhalla, Shannon, Nanda, Rita, Storniolo, Anna Maria, Carey, Lisa A., Saleh, Mansoor N., Li, Yufeng, Delossantos, Jennifer F., Grizzle, William E., LoBuglio, Albert F., Myers, Richard M., Forero-Torres, Andres
Publicado 2020

FOXA1 and adaptive response determinants to HER2 targeted therapy in TBCRC 036

por Angus, Steven P., Stuhlmiller, Timothy J., Mehta, Gaurav, Bevill, Samantha M., Goulet, Daniel R., Olivares-Quintero, J. Felix, East, Michael P., Tanioka, Maki, Zawistowski, Jon S., Singh, Darshan, Sciaky, Noah, Chen, Xin, He, Xiaping, Rashid, Naim U., Chollet-Hinton, Lynn, Fan, Cheng, Soloway, Matthew G., Spears, Patricia A., Jefferys, Stuart, Parker, Joel S., Gallagher, Kristalyn K., Forero-Torres, Andres, Krop, Ian E., Thompson, Alastair M., Murthy, Rashmi, Gatza, Michael L., Perou, Charles M., Earp, H. Shelton, Carey, Lisa A., Johnson, Gary L.
Publicado 2021

Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a ra...

por Barroso-Sousa, Romualdo, Tarantino, Paolo, Tayob, Nabihah, Dang, Chau, Yardley, Denise A., Isakoff, Steven J., Valero, Vicente, Faggen, Meredith, Mulvey, Therese, Bose, Ron, Hu, Jiani, Weckstein, Douglas, Wolff, Antonio C., Reeder-Hayes, Katherine, Rugo, Hope S., Ramaswamy, Bhuvaneswari, Zuckerman, Dan, Hart, Lowell, Gadi, Vijayakrishna K., Constantine, Michael, Cheng, Kit, Briccetti, Frederick, Schneider, Bryan, Garrett, Audrey Merrill, Marcom, Kelly, Albain, Kathy, DeFusco, Patricia, Tung, Nadine, Ardman, Blair, Nanda, Rita, Jankowitz, Rachel C., Rimawi, Mothaffar, Abramson, Vandana, Pohlmann, Paula R., Van Poznak, Catherine, Forero-Torres, Andres, Liu, Minetta, Ruddy, Kathryn J., Zheng, Yue, Rosenberg, Shoshana M., Gelber, Richard D., Trippa, Lorenzo, Barry, William, DeMeo, Michelle, Burstein, Harold, Partridge, Ann, Winer, Eric P., Krop, Ian, Tolaney, Sara M.
Publicado 2022

Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2(+) breast cancer in the adaptively randomized I-SPY2 trial

por Clark, Amy S., Yau, Christina, Wolf, Denise M., Petricoin, Emanuel F., van ‘t Veer, Laura J., Yee, Douglas, Moulder, Stacy L., Wallace, Anne M., Chien, A. Jo, Isaacs, Claudine, Boughey, Judy C., Albain, Kathy S., Kemmer, Kathleen, Haley, Barbara B., Han, Hyo S., Forero-Torres, Andres, Elias, Anthony, Lang, Julie E., Ellis, Erin D., Yung, Rachel, Tripathy, Debu, Nanda, Rita, Wulfkuhle, Julia D., Brown-Swigart, Lamorna, Gallagher, Rosa I., Helsten, Teresa, Roesch, Erin, Ewing, Cheryl A., Alvarado, Michael, Crane, Erin P., Buxton, Meredith, Clennell, Julia L., Paoloni, Melissa, Asare, Smita M., Wilson, Amy, Hirst, Gillian L., Singhrao, Ruby, Steeg, Katherine, Asare, Adam, Matthews, Jeffrey B., Berry, Scott, Sanil, Ashish, Melisko, Michelle, Perlmutter, Jane, Rugo, Hope S., Schwab, Richard B., Symmans, W. Fraser, Hylton, Nola M., Berry, Donald A., Esserman, Laura J., DeMichele, Angela M.
Publicado 2021

Safety and efficacy of HSP90 inhibitor ganetespib for neoadjuvant treatment of stage II/III breast cancer

por Lang, Julie E., Forero-Torres, Andres, Yee, Douglas, Yau, Christina, Wolf, Denise, Park, John, Parker, Barbara A., Chien, A. Jo, Wallace, Anne M., Murthy, Rashmi, Albain, Kathy S., Ellis, Erin D., Beckwith, Heather, Haley, Barbara B., Elias, Anthony D., Boughey, Judy C., Yung, Rachel L., Isaacs, Claudine, Clark, Amy S., Han, Hyo S., Nanda, Rita, Khan, Qamar J., Edmiston, Kristen K., Stringer-Reasor, Erica, Price, Elissa, Joe, Bonnie, Liu, Minetta C., Brown-Swigart, Lamorna, Petricoin, Emanuel F., Wulfkuhle, Julia D., Buxton, Meredith, Clennell, Julia L., Sanil, Ashish, Berry, Scott, Asare, Smita M., Wilson, Amy, Hirst, Gillian L., Singhrao, Ruby, Asare, Adam L., Matthews, Jeffrey B., Melisko, Michelle, Perlmutter, Jane, Rugo, Hope S., Symmans, W. Fraser, van ‘t Veer, Laura J., Hylton, Nola M., DeMichele, Angela M., Berry, Donald A., Esserman, Laura J.
Publicado 2022